An 80-year-old man underwent percutaneous coronary intervention with a bare-metal stent for severe stenosis at proximal left anterior descending coronary artery 13 years ago. In-stent restenosis was treated by a drug-eluting stent 1 year later...

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

Transcatheter interventions have rapidly reshaped the management of tricuspid valve disease, with landmark trials establishing feasibility and early clinical benefit.

Beyond these pivotal studies, a series of less visible but highly informative papers addressed mechanisms, complications, patient phenotypes, and unintended consequences of intervention.

This curated selection highlights ten impactful tricuspid...